|Day Low/High||8.95 / 9.05|
|52 Wk Low/High||2.94 / 14.90|
An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012.
These under-$10 stocks look poised to trade higher from current levels.
These stocks look poised to break out and trade higher from current prices.
Raptor's RP103 designed to be more convenient for patients with ultra-rare genetic disorder.
These market-leading stocks could see massive short squeezes on any positive catalyst.
These looming FDA drug approvals and clinical trial results are pivotal events in the lifeline of a biotech company.
Data From Trial Expected to be Released in Second Quarter of 2011
Over 30 Patients Expected to Complete Eight-Week Study Protocol
Contracts in Place for Cambrex Corporation and Patheon, Inc. to Manufacture Active Pharmaceutical Ingredient and Commercial Product, Respectively
Raptor Announces Grant Award and NeuroTrans(TM) IP Update
The BSMRP, a portfolio of biotech and drug stocks chosen by readers of my weekly Mailbag, is down 23% this year.
Here's a list of drug and biotech firms with impending clinical trials results.
Uni Pharma to Market Convivia(TM) in Taiwan
Randomized, Crossover Study to Evaluate DR Cysteamine as a Lower-Dose, More Tolerable Alternative to Immediate-Release Cysteamine
Potential for 10 Years Market Exclusivity in E.U.
Several stocks trading near $5 were moving on above-average volume during Monday's session.
Several stocks trading near $5 were moving on above-average volume during Friday's session.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.